The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...

Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to ...

As the first second-generation INSTI approved for newborns with HIV, this approval allows for a simpler, more robust antiretroviral therapy regimen than existing standard of care.

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3 ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD ...

As of July 2026, there have been 34 newly diagnosed cases of HIV this year and 50% are reported among individuals who inject drugs.

For years, Philip Goulder has been obsessed with a particularly captivating idea: In the hunt for an HIV cure, could children hold the answers? Starting in the mid-2010s, the University of Oxford ...

In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the ...

John Eliasu Mahama, Acting Director of Policy and Planning at the Ghana AIDS Commission (GAC), has called on institutions to ...